#3 - AbbVie (NYSE:ABBV)
If investors are looking for a more reasonably valued pharmaceutical stock, AbbVie Inc. (NYSE: ABBV) is one to consider. ABBV stock has a forward P/E of around 17x, which correlates well with the anticipated 11.79% earnings growth in the next 12 months.
AbbVie's flagship drug, Humira, is used to treat rheumatoid and psoriatic arthritis. Concerns about biosimilar competition are real, but the company planned for this well in advance. And its Skyrizi and Rinvoq are showing signs of offsetting revenue decline from Humira.
AbbVie is also a good example of why investors don’t have to compromise growth with a low beta stock. The company has delivered a total return of over 435% in the last 10 years. That’s nearly double that of Regeneron. Plus, AbbVie is a dividend king that has increased its dividend for 52 consecutive years with a current yield of 3.18%. A rock-solid balance sheet means that dividend is not at risk.
About AbbVie
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Read More - Current Price
- $175.58
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 19 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $205.70 (17.2% Upside)
